Anthropic has initiated its own drug discovery programs focusing on diseases that major pharmaceutical companies often overlook due to low profitability, according to The Decoder. This move marks a notable shift as the company aims to address unmet medical needs in less commercially attractive areas.
Novartis CEO Vas Narasimhan highlighted the potential of AI in drug development, suggesting it could reduce the typical development timeline from twelve years to seven or eight years. Additionally, he noted that AI might double the success rate of drug approvals from 8 percent to 16 percent, underscoring the transformative impact of artificial intelligence on the pharmaceutical industry.
For Japanese investors and markets, this development signals growing AI-driven innovation in healthcare, a sector where Japan has been actively investing to improve drug development efficiency and address an aging population's needs.